Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT01303341 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Riluzole and Sorafenib Tosylate in Treating Patients With Advanced Solid Tumors or Melanoma

StatusActive, Not Recruiting
PhasePhase 1
Started
View on ClinicalTrials.gov ↗

Record History

The 50 most recent of 104 record versions are accounted for below. See every version on ClinicalTrials.gov ↗

  1. Completion pushed from Sep 17, 2026 to Sep 11, 2027
  2. 21 versions Re-verified since Mar 12, 2026, no change to tracked fieldsv83-v103
  3. Completion date: Sep 17, 2025 to Sep 17, 2026v82
  4. 2 versions Re-verified since Mar 15, 2025, no change to tracked fieldsv80-v81
  5. Completion date: Sep 9, 2024 to Sep 17, 2025v79
Show 24 earlier versionsHide 24 earlier versions
  1. 2 versions Re-verified since Mar 20, 2024, no change to tracked fieldsv77-v78
  2. Completion date: Sep 9, 2023 to Sep 9, 2024v76
  3. 2 versions Re-verified since Sep 15, 2022, no change to tracked fieldsv74-v75
  4. Enrollment target: estimated 36 to confirmed 35 Primary completion date changed from estimate of Aug 1, 2022 to May 1, 2012 · Completion date: Aug 1, 2022 to Sep 9, 2023v73 Show 2 more changesShow less
    • Primary completion date changed from estimate of Aug 1, 2022 to May 1, 2012
    • Completion date: Aug 1, 2022 to Sep 9, 2023
  5. 2 versions Re-verified since Jun 7, 2022, no change to tracked fieldsv71-v72
  6. Primary and study completion dates: May 1, 2022 to Aug 1, 2022v70
  7. Primary and study completion dates: Jan 15, 2022 to May 1, 2022v69
  8. Primary and study completion dates: Nov 1, 2021 to Jan 15, 2022v68
  9. Primary and study completion dates: Aug 1, 2021 to Nov 1, 2021v67
  10. Primary completion date: Apr 16, 2018 to Aug 1, 2021 Enrollment target: 35 to 36 · Completion date: Aug 1, 2021v66 Show 2 more changesShow less
    • Enrollment target: 35 to 36
    • Completion date: Aug 1, 2021
  11. 2 versions Re-verified since Oct 2, 2020, no change to tracked fieldsv64-v65
  12. Enrollment target: estimated 36 to confirmed 35 Primary completion date changed from estimate of Jun 1, 2020 to Apr 16, 2018v63 Show 1 more changeShow less
    • Primary completion date changed from estimate of Jun 1, 2020 to Apr 16, 2018
  13. 2 versions Re-verified since Apr 2, 2020, no change to tracked fieldsv61-v62
  14. Primary completion date: Mar 1, 2020 to Jun 1, 2020v60
  15. 3 versions Re-verified since Jan 20, 2020, no change to tracked fieldsv57-v59
  16. Primary completion date: Dec 1, 2019 to Mar 1, 2020v56
  17. Re-verified, no change to tracked fieldsv55
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This phase I trial studies the side effects and best dose of sorafenib tosylate when given together with riluzole in treating patients with solid tumors or melanoma that has spread to other places in the body and usually cannot be cured or controlled with treatment. Riluzole may stop or slow the growth of tumor cells. Sorafenib tosylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving riluzole together with sorafenib tosylate may kill more tumor cells.
Trial Details
NCT Number NCT01303341
Lead Sponsor National Cancer Institute (NCI)
Conditions Advanced Malignant Solid Neoplasm, Recurrent Melanoma, Refractory Malignant Solid Neoplasm, Stage III Cutaneous Melanoma AJCC v7, Stage IIIA Cutaneous Melanoma AJCC v7, Stage IIIB Cutaneous Melanoma AJCC v7, Stage IIIC Cutaneous Melanoma AJCC v7, Stage IV Cutaneous Melanoma AJCC v6 and v7
Enrollment 35 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov